Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy.
An esophageal lead was used to perform decremental atrial pacing and elective induction of atrial fibrillation (AF) in 5 patients with the Wolff-Parkinson-White (W-P-W) syndrome before and after amiodarone therapy. In the control state, 1:1 atrioventricular (AV) conduction over the accessory pathway ranged from 220 to 260 ms (mean 232). The shortest R-R interval during AF ranged from 190 to 210 ms (mean 198). The ventricular rate ranged from 175 to 212 beats/min (mean 196). After amiodarone therapy, the shortest cycle length with 1:1 AV conduction increased in all patients, ranging from 290 to 540 ms (mean 370); during AF, no preexcited beat was present in 2 patients, whereas the minimal preexcited R-R interval in the remaining 3 was 290, 240, and 370 ms, respectively. The ventricular response during AF decreased in all patients. Thus, esophageal pacing is a useful method for identifying patients at risk with the W-P-W syndrome and for assessing appropriate management in individual patients. Amiodarone provides protection against life-threatening arrhythmias in these patients.
D000293:Adolescent; D000328:Adult; D000638:Amiodarone / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D003645:Death, Sudden / Q000209:etiology; D004947:Esophagus; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D011802:Quinidine / Q000627:therapeutic use; D014927:Wolff-Parkinson-White Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery
D011802:Quinidine; D000638:Amiodarone